Posts Tagged: MaRS Discovery District

Johnson & Johnson Innovation Opens JLABS @ Toronto

TORONTO (May 11, 2016) –  Johnson & Johnson Innovation LLC, today announced the opening of JLABS @ Toronto, a new 40,000-square-foot life sciences incubator, providing entrepreneurs shared lab space and offices, modular lab suites and access to scientific, industry and capital funding experts as they work to build important and successful early-stage companies. The new JLABS facility can accommodate up to 50 start-ups and opens with 22 companies that represent a range of sectors including therapeutics, medical devices and consumer health ... Read more

TrendMD graduates from Ycombinator and announces new partnerships

It’s been a busy quarter for UTEST company TrendMD. Fresh off their participation in Ycombinator’s Winter 2016 cohort, which was covered in TechCrunch, the company has announced partnerships with HighWire and Integra. TrendMD, a Canadian start-up company, is a content recommendation engine for scholarly publishers. They work with over 2,000 medical journals by organizing and tailoring information to the appropriate audiences. This functionality creates several opportunities for various researchers to promote their research and clinical practices in their respective fields. TrendMD launched through ... Read more

Triphase Accelerator Corporation expands collaboration with Celgene in developing Marizomib to treat gliomas

Company initiating two new clinical trials for recurrent and newly diagnosed malignant gliomas TORONTO and SAN DIEGO, (May 03, 2016) – Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that it is expanding its current collaboration with Celgene Corp. in the development of marizomib for the potential treatment of malignant gliomas. The two companies will collaborate on a Phase 2 study using marizomib (MRZ) as monotherapy in recurrent glioblastoma, as well as a Phase ... Read more

Miroculus acquires Kapplex to advance diagnostics for complex diseases

Canadian innovation will give patients affordable, non-invasive, accurate test for cancer or infectious diseases; R&D team to remain in Toronto discovery district TORONTO and SAN FRANCISCO (May 3, 2016) — Miroculus, a San Francisco-based biotechnology company specializing in microRNA-based diagnostics, today announced an agreement to acquire Toronto-based Kapplex Inc. The Canadian company’s proprietary Digital Microfluidic (DMF) platform is built upon the research of Dr. Aaron Wheeler, a world-leader in microfluidics research at the University of Toronto. This announcement was covered in GenomeWeb and PeHub. When ... Read more

Triphase to present Marizomib clinical and preclinical data at American Society of Hematology’s annual meeting

TORONTO and SAN DIEGO (December 8, 2015) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that positive results from its ongoing Phase 1 proof-of-concept study evaluating marizomib in patients with relapsed and refractory multiple myeloma will be presented at the 57th Annual Meeting of the American Society of Hematology (ASH). The company will also present preclinical data on marizomib demonstrating synergistic activity in combination with pomalidomide. Marizomib is a novel ... Read more

Triphase secures FDA orphan drug designation for Marizomib in Malignant Glioma

TORONTO and SAN DIEGO (November 19, 2015) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for marizomib to treat patients with malignant glioma. Malignant glioma is an aggressive form of brain cancer for which there is a significant unmet need in current treatments due to the disease's poor prognosis. Triphase is evaluating marizomib, a novel and highly ... Read more

Triphase announces Health Canada approval to initiate Marizomib Phase 1 study in recurrent glioma patients

TORONTO and SAN DIEGO (September 25, 2015) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that it has received approval from Health Canada to initiate its Phase 1 clinical study of marizomib in combination with bevacizumab (Avastin®) in patients with recurrent malignant glioma in Canada. Marizomib is a novel and highly potent proteasome inhibitor that readily penetrates the blood brain barrier. It prevents the breakdown of proteins involved in signal ... Read more

Ontario Government, University of Toronto, and MaRS secure Johnson & Johnson Innovation, JLABS for Toronto – first JLABS Incubator outside of United States

Partners for JLABS @ Toronto include Janssen Inc., MaRS Innovation and seven of MI's 15 member institutions   TORONTO, Sept. 8, 2015 — The Ontario Government, University of Toronto, and MaRS Discovery District (MaRS) today announced a collaboration with Janssen Inc. to launch the successful Johnson & Johnson Innovation, JLABS incubator model in Toronto. This announcement has been covered in the Toronto Star, Metro News Canada, Sing Tao Daily, OurWindsor.ca, FierceBiotech, BioCentury, MedCity News, BioSpace, Biotechnology Focus, Lab Product News, ChinaNews.com, Pan European Networks, Economic ... Read more

The Varsity on UTEST and start-up culture at U of T; Whirlscape launches new Minuum smartwatch demo

"Start-up culture is fast taking hold at U of T, with an array of incubators and accelerators providing student entrepreneurs the resources and mentorships required to get their businesses up and running," writes Ameya Charnalia of The Varsity, the University of Toronto's student newspaper. Charnalia's article focuses on new student-focused incubators, such as the UTEST program, which provide entrepreneurs cash, access to in-house expertise, working space and mentorship to advice their ideas. It appeared in the same week that recent UTEST graduate Whirlscape released ... Read more

QSperm: Technology to help couples get pregnant faster

MaRS Innovation and U of T's Innovations & Partnerships Office collaborating with QSperm on intellectual property and business strategy In vitro fertility treatments can be intensely emotional and medically invasive, not to mention expensive. But technical developments from a research group at the University of Toronto may soon be able to shorten the journey to pregnancy – and that potential has piqued interest from international investors. The research group, QSperm, is looking to turn their research into a biotech start-up leveraging an innovative sperm sorting design ... Read more
Page 1 of 41234